

10/ 539,481

1/2

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/Caplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/Caplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/Caplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 18 CA/Caplus to be enhanced with pre-1967 CAS Registry Numbers

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:35:40 ON 22 JUN 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

10/ 539,481

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:35:54 ON 22 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3
DICTIONARY FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10539481.str



chain nodes :
11 12 13 16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
5-17 7-11 11-16 12-13 17-18 18-19 19-20
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
exact/norm bonds :
5-17 7-11 11-16 12-13 17-18 19-20
exact bonds :
18-19
normalized bonds :

10/ 539,481

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
isolated ring systems :
containing 1 :

G1:O,S,N,SO2, [*1]

G2:N,P,Cy

Hydrogen count :

9:=exact 1

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:CLASS 12:CLASS 13:CLASS 16:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS

Generic attributes :

16:

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic.

Element Count :

Node 16: Limited

C,C3-4

S,S1


N,N0-3

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N,SO2, [@1]

G2 N,P,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:36:32 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1816 TO ITERATE

100.0% PROCESSED 1816 ITERATIONS

SEARCH TIME: 00.00.01

31 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 33764 TO 38876

10/ 539,481

PROJECTED ANSWERS: 286 TO 954

L2 31 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 11:36:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 36537 TO ITERATE

100.0% PROCESSED 36537 ITERATIONS
SEARCH TIME: 00.00.01

584 ANSWERS

L3 584 SEA SSS FUL L1

=> file zcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'ZCAPLUS' ENTERED AT 11:36:47 ON 22 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2007 VOL 147 ISS 1

FILE LAST UPDATED: 21 Jun 2007 (20070621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 4 L3

=> d his

(FILE 'HOME' ENTERED AT 11:35:40 ON 22 JUN 2007)

FILE 'REGISTRY' ENTERED AT 11:35:54 ON 22 JUN 2007

L1 STRUCTURE UPLOADED

L2 31 S L1

L3 584 S L1 FUL

FILE 'ZCAPLUS' ENTERED AT 11:36:47 ON 22 JUN 2007

L4 4 S L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:527454 ZCAPLUS

DOCUMENT NUMBER: 146:501073

TITLE: Preparation of quinazolinylaminothiazoles as protein kinase inhibitors for treatment of cancer.

INVENTOR(S): Ehlert, Jan; Herz, Thomas; Krauss, Rolf; Kubbutat, Michael; Lang, Martin; Pegoraro, Stefano; Schaechtele, Christoph; Totzke, Frank; Zirrgiebel, Ute

PATENT ASSIGNEE(S): 4SC AG, Germany

SOURCE: Eur. Pat. Appl., 31pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1785420	A1	20070516	EP 2005-24847	20051114
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
WO 2007054357	A1	20070518	WO 2006-EP10870	20061113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2005-24847 A 20051114
GI



AB Title compds. [I; R¹ = CR⁶R⁷(CR⁸R⁹)_nAR⁵; R² = H, halo, cyano, alkyl, alkoxy, haloalkoxy, alkylamino; R³ = (substituted) quinazolinyl, quinolyl, pyrimidyl, triazinyl, pyridyl, etc.; X = S, O, NR⁴, SO, SO₂; n = 1-3; A = CO, CS, SO, SO₂, CO₂, CONR¹², etc.; R⁵ = H, alkyl, cycloalkyl aryl, heteroaryl, etc.; R⁶ = H, halo cyano, OH, amino, alkyl, alkoxy,

haloalkoxy, cycloalkyl, etc.; R7 = H, halo, cyano, OH, amino, alkyl, alkoxy cycloalkyl, haloalkoxy, etc.; R8 = H, halo, cyano, OH, amino, alkyl, alkoxy, alkylamino, cycloalkyl, haloalkyl, etc.; R6R8 = atoms to form a 3-8 membered (substituted) (hetero)cyclyl; R12 = H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl], were prepared Title compds. e.g. (II) (preparation outlined) inhibited ≥ 1 protein kinase with IC50 <500 nM.


IT 936449-18-2P 936449-19-3P 936449-22-8P
936449-23-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolinylaminothiazoles as protein kinase inhibitors for treatment of cancer)

RN 936449-18-2 ZCAPLUS


CN Benzamide, 3-fluoro-N-[2-[2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 936449-19-3 ZCAPLUS


CN Benzamide, N-[2-[2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 936449-22-8 ZCAPLUS


CN 5-Thiazolepropanamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 936449-23-9 ZCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:20543 ZCAPLUS

DOCUMENT NUMBER: 144:292702

TITLE: Discovery of Novel and Potent Thiazoloquinazolines as
 Selective Aurora A and B Kinase Inhibitors

AUTHOR(S): Jung, Frederic H.; Pasquet, Georges; Van der Brempt,
 Christine Lambert; Lohmann, Jean-Jacques M.; Warin,
 Nicolas; Renaud, Fabrice; Germain, Herve; De Savi,
 Chris; Roberts, Nicola; Johnson, Trevor; Dousson,
 Cyril; Hill, George B.; Mortlock, Andrew A.; Heron,
 Nicola; Wilkinson, Robert W.; Wedge, Stephen R.;
 Heaton, Simon P.; Odedra, Rajesh; Keen, Nicholas J.;
 Green, Stephen; Brown, Elaine; Thompson, Katherine;
 Brightwell, Stephen

CORPORATE SOURCE: Centre de Recherches, AstraZeneca, Reims, 51689, Fr.
 SOURCE: Journal of Medicinal Chemistry (2006), 49(3), 955-970
 CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:292702

AB The synthesis of a novel series of quinazolines substituted at C4 by
 five-membered ring aminoheterocycles is reported. Their in vitro
 structure-activity relationships vs. Aurora A and B serine-threonine
 kinases is discussed. Our results demonstrate that quinazolines with a
 substituted aminothiazole at C4 possess potent Aurora A and B inhibitory
 activity and excellent selectivity against a panel of various
 serine-threonine and tyrosine kinases, as exemplified by
 N-(3-fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-
 methoxy-quinazolinyl]amino]-1,3-thiazol-5-yl]acetamide (I). It was found
 also that the position and nature of the substituent on the thiazole play
 key roles in cellular potency. Compds. with an acetanilide substituent at
 C5' have the greatest cellular activity. The importance of the C5'
 position for substitution has been rationalized by ab initio MO calcns.
 Results show that the planar conformation with the sulfur of the thiazole
 next to the quinazoline N-3 is strongly favored over the other possible
 planar conformation. I is a potent suppressor of the expression of
 phospho-histone H3 in tumor cells in vitro as well as in vivo, where I,
 administered as its phosphate prodrug suppresses the expression of
 phospho-histone H3 in s.c. implanted tumors in nude mice.

IT 878375-97-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(amidation of thiazoleacetate ester derivative in preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 878375-97-4 ZCAPLUS

CN 5-Thiazoleacetic acid, 2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385784-81-6P 385785-60-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(amidation of thiazoleacetic acid derivative with fluoroaniline in preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385784-81-6 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385785-60-4 ZCAPLUS

CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385780-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(amidation of thiazolecarboxylic acid derivative with fluoroaniline in preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385780-24-5 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 723278-14-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(hydrolysis of [(quinazolinyl)oxy]propyl]piperidinylmethyl phosphate ester in preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 723278-14-6 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385782-89-8P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (aminoalkoxy) [(heterocyclic) amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385782-89-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


10/ 539,481

IT 385779-87-3P 385781-84-0P 385782-93-4P
385782-97-8P 385784-57-6P 385784-59-8P
723278-11-3P 723278-79-3P 723279-41-2P
723281-54-7P 723282-96-0P 878375-90-7P
878375-91-8P 878375-92-9P 878375-95-2P
878375-98-5P 878375-99-6P 878376-00-2P
878376-04-6P 878376-05-7P 878376-08-0P
878376-09-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors
of aurora A and B kinase)

RN 385779-87-3 ZCAPLUS


CN 5-Thiazolecarboxamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-
morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-84-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-
piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-93-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-97-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-ethyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-57-6 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-(5-methyl-2-thiazolyl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-59-8 ZCAPLUS


CN 4-Quinazolinamine, N-(5-butyl-2-thiazolyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-11-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-79-3 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-41-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-54-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-96-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[2-[4-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-90-7 ZCAPLUS


CN 4-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-91-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-92-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-95-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,481




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-98-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-99-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-[3-(dimethylamino)phenyl]-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,481




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-00-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-[2-(aminocarbonyl)phenyl]-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-04-6 ZCAPLUS

CN 4-Piperidinemethanol, 1-[3-[[4-[[5-(3-fluorophenoxy)-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-05-7 ZCAPLUS


CN 4-Piperidinemethanol, 1-[3-[[4-[[5-[[3-(3-fluorophenyl)methyl]thio]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-08-0 ZCAPLUS


CN Benzamide, 3-fluoro-N-[[2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-09-1 ZCAPLUS

CN Benzenesulfonamide, 3-fluoro-N-[[2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-5-thiazolyl]methyl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385780-20-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(saponification of thiazoleacetate derivative in preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385780-20-1 ZCAPLUS

CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-

quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385784-82-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(saponification of thiazoleacetate ester derivative in preparation of (aminoalkoxy) [(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385784-82-7 ZCAPLUS

CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385780-23-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(saponification of thiazolecarboxylate derivative in preparation of (aminoalkoxy) [(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385780-23-4 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:566600 ZCAPLUS

DOCUMENT NUMBER: 141:123646

TITLE: Preparation of quinazolines as inhibitors of Aurora kinase

INVENTOR(S): Mortlock, Andrew Austen

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058752	A1	20040715	WO 2003-GB5636	20031222
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2508921	A1	20040715	CA 2003-2508921	20031222
AU 2003290322	A1	20040722	AU 2003-290322	20031222
EP 1575946	A1	20050921	EP 2003-782681	20031222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003017680	A	20051129	BR 2003-17680	20031222
CN 1753889	A	20060329	CN 2003-80109899	20031222
JP 2006516138	T	20060622	JP 2004-563353	20031222
NO 2005002991	A	20050719	NO 2005-2991	20050617
US 2006058523	A1	20060316	US 2005-539481	20050617
PRIORITY APPLN. INFO.:			EP 2002-293239	A 20021224
			WO 2003-GB5636	W 20031222

OTHER SOURCE(S): MARPAT 141:123646

GI

PG Pub.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = 5-membered heteroaryl; X = O, SOO-2, amino; m = 0-3; Z = amino, phosphonooxy, cycloalkyl, etc.; R3 = H, halo, CN, NO2, etc.; R4 = H, alkyl, heteroaryl, etc.; R5 = H, alk(en/yn)yl, cycloalkyl, etc.; R6-7 = H, halo, alkyl, etc.] are prepared For instance, N'-[5-(3-chloropropoxy)-2-cyano-4-methoxyphenyl]-N,N-dimethylimidoforamide (preparation given) is reacted with tert-Bu [5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]carbamate (HOAc, reflux, 2 h) to give the corresponding quinazoline. This is used to alkylate (piperidin-4-yl)methanol and the resulting product reacted with tetrazole and di-tert-butyl-diethylphosphoramidite. Treatment of this penultimate intermediate with 4N HCl afforded II. Compds. of the invention have IC50 in the range of 0.3 nM to 1000 nM for Aurora-B kinase.

IT 723278-08-8P 723278-11-3P, [1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]methyl dihydrogen phosphate 723278-42-0P, (R)-[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723278-50-0P, 2-[4-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperazin-1-yl]ethyl dihydrogen phosphate 723278-57-7P, [1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-3-yl] dihydrogen phosphate 723278-65-7P, 1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-3-yl] dihydrogen phosphate 723278-73-7P, 2-[Ethyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723278-82-8P 723278-85-1P, (S)-[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723278-93-1P, (S)-2-[N-Ethyl-N-[[1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl]amino]ethyl dihydrogen phosphate 723279-10-5P, 1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl] dihydrogen phosphate 723279-18-3P, (S)-2-[[[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl]amino]ethyl dihydrogen phosphate 723279-35-4P, 2-[[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723279-47-8P, 3-[Ethyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]propyl dihydrogen phosphate 723279-56-9P, 2-[(2-Fluoroethyl)[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723279-65-0P, 2-[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]ethyl dihydrogen phosphate 723279-73-0P, 2-[[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]](2-methoxyethyl)amino]ethyl dihydrogen phosphate 723279-82-1P, (S)-2-[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]ethyl dihydrogen phosphate 723279-91-2P, 2-[[3-[[4-[[5-[2-[(3-

Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]-2-methylpropyl dihydrogen phosphate 723279-99-0P, (R)-[1-[3-[[4-[[5-[2-[(3-Chlorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723280-18-0P, 2-[1-[3-[[4-[[5-[2-[(3-Chlorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]ethyl dihydrogen phosphate 723280-26-0P, 2-[4-[3-[[4-[[5-[2-[(3,5-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperazin-1-yl]ethyl dihydrogen phosphate 723280-38-4P, 2-[[3-[[4-[[5-[2-[(3,5-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]methyl]ethyl dihydrogen phosphate 723280-46-4P, (S)-[1-[3-[[4-[[5-[2-[(3,5-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723280-54-4P 723280-65-7P; (R)-[1-[3-[[4-[[5-[2-[(3,4-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723280-82-8P, (S)-[1-[3-[[4-[[5-[2-[(3,4-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723280-93-1P, 1-[3-[[4-[[5-[2-[(3,4-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]methyl dihydrogen phosphate 723281-02-5P 723281-04-7P, [1-[3-[[4-[[5-[2-[(2-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]methyl dihydrogen phosphate 723281-15-0P 723281-16-1P, (R)-[1-[3-[[4-[[5-[2-[(2-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723281-21-8P 723281-23-0P, (S)-[1-[3-[[4-[[5-[2-[(2-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723281-28-5P 723281-30-9P, 2-[Ethyl[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723281-34-3P 723281-35-4P, 2-[1-[3-[[4-[[5-[2-[(2-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-2-yl]ethyl dihydrogen phosphate 723281-38-7P 723281-39-8P, (R)-[1-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723281-49-0P 723281-51-4P, (S)-[1-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723281-56-9P 723281-58-1P, 2-[[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]methyl]amino]ethyl dihydrogen phosphate 723281-62-7P 723281-64-9P, 2-[1-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-2-yl]ethyl dihydrogen phosphate 723281-69-4P 723281-71-8P, 2-[[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]methyl]ethyl dihydrogen phosphate 723281-77-4P, 1-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]methyl dihydrogen phosphate 723281-82-1P, 2-[4-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperazin-1-yl]ethyl dihydrogen phosphate 723281-88-7P, 3-[[3-[[4-[[5-[2-[(2,3-

Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]-3-methylbutyl dihydrogen phosphate 723281-94-5P, 2-[[[3-[[[4-[[[5-[2-[(2,3-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]-2-methylpropyl dihydrogen phosphate 723282-00-6P, 2-[[[3-[[[4-[[[5-[2-[(2,3-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723282-06-2P 723282-08-4P, (R)-[1-[3-[[[4-[[[5-[2-[(2,5-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723282-20-0P 723282-21-1P, (S)-[1-[3-[[[4-[[[5-[2-[(2,5-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723282-26-6P 723282-28-8P, 2-[[[3-[[[4-[[[5-[2-[(2,5-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl] (ethyl) amino]ethyl dihydrogen phosphate 723282-34-6P, (S)-[1-[3-[[[4-[[[5-[2-[(2,4-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723282-45-9P, 2-[1-[3-[[[4-[[[5-[2-[(2,4-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-2-yl]ethyl dihydrogen phosphate 723282-51-7P, 2-[Cyclopropyl[3-[[[4-[[[5-[2-[(3-fluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723282-57-3P, 2-[Cyclopropyl[3-[[[4-[[[5-[2-[(2,3-difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723282-63-1P, [1-[2-[[[4-[[[5-[2-[(2,3-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]piperidin-4-yl]methyl dihydrogen phosphate 723282-73-3P 723282-75-5P, (R)-[1-[2-[[[4-[[[5-[2-[(2,3-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723282-79-9P, 2-[4-[2-[[[4-[[[5-[2-[(2,3-Difluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]piperazin-1-yl]ethyl dihydrogen phosphate 723282-85-7P 723282-87-9P, 2-[1-[2-[[[4-[[[5-[2-[(3-Fluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]piperidin-2-yl]ethyl dihydrogen phosphate 723282-94-8P, 2-[1-[2-[[[4-[[[5-[2-[(3-Fluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]piperidin-4-yl]ethyl dihydrogen phosphate 723282-98-2P, 4-[Ethyl[2-[[[4-[[[5-[2-[(3-fluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]amino]butyl dihydrogen phosphate 723283-03-2P, 2-[Ethyl[2-[[[4-[[[5-[2-[(3-fluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]amino]ethyl dihydrogen phosphate 723283-07-6P 723283-08-7P, [1-[3-[[[4-[[[5-[2-[(3-Fluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]quinazolin-7-yl]oxy]propyl]piperidin-4-yl]methyl dihydrogen phosphate 723283-17-8P 723283-19-0P, 2-[4-[[[[4-[[[5-[2-[(3-Fluorophenyl) amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]methyl]piperidin-1-yl]ethyl dihydrogen phosphate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of quinazolines as inhibitors of Aurora kinase)

RN 723278-08-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[[6-methoxy-7-[3-[4-[(phosphonooxy)methyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-,

dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-11-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[(phosphonooxy)methyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)




10/ 539,481

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-42-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-50-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonoxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-57-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[3-(phosphonoxy)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-65-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[3-(phosphonooxy)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-73-7 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-82-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-85-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-93-1 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[(2S)-2-[[ethyl[2-(phosphonoxy)ethyl]amino]methyl]-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-10-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-(phosphonoxy)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-18-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[[[2-(phosphonooxy)ethyl]amino]methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




10/ 539,481

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-35-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-47-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl[3-(phosphonooxy)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-56-9 ZCAPLUS

10/ 539,481


CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-fluoroethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-65-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonooxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-73-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2-

10/ 539,481

methoxyethyl) [2- (phosphonooxy) ethyl] amino] propoxy] -4-quinazolinyl] amino] -
(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-82-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[2-(phosphonooxy)ethyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI)
(CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-91-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[[1,1-dimethyl-2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-99-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-18-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-26-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonooxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-38-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[methyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-46-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-54-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[[[(2R)-2-(phosphonooxy)propyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-65-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-82-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,481

RN 723280-93-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-{3-[4-(phosphonooxy)-1-piperidinyl]propoxy}-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-02-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-{3-[4-(phosphonooxy)methyl]-1-piperidinyl]propoxy}-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




PAGE 1-A

● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-04-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[4-
[(phosphonooxy)methyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino] - (9CI)
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-15-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-
[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino] -,
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,481

RN 723281-16-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-21-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-23-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-28-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2-fluorophenyl)-, dihydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-30-9 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-34-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-35-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-38-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-39-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,481




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-49-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-51-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-56-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[methyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-58-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[methyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-62-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-64-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI)

(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-69-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-{3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-71-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[ethyl[2-(phosphonoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino] - (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-77-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[4-(phosphonoxy)-1-piperidinyl]propoxy]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-82-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonooxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-88-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[[1,1-dimethyl-3-(phosphonooxy)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-94-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[[1,1-dimethyl-2-(phosphonoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-00-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[[2-(phosphonoxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-06-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-08-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-20-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-21-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-26-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[ethyl(2-(phosphonoxy)ethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-28-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[ethyl(2-(phosphonoxy)ethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-34-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-45-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonooxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




|
F

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-51-7 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[cyclopropyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-57-3 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[[7-[3-[cyclopropyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-63-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[[6-methoxy-7-[2-[4-[(phosphonooxy)methyl]-1-piperidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-73-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[2-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]ethoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-75-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[2-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-79-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[2-[4-[2-(phosphonoxy)ethyl]-1-piperazinyl]ethoxy]-4-quinazolinyl]amino]-(9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-85-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[2-[2-[2-(phosphonoxy)ethyl]-1-piperidinyl]ethoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-87-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[2-[2-(2-(phosphonooxy)ethyl]-1-piperidinyl]ethoxy]-4-quinazolinyl]amino] - (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-94-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[2-[4-[2-(phosphonooxy)ethyl]-1-piperidinyl]ethoxy]-4-quinazolinyl]amino] - (9CI)
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-07-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-[(phosphonoxy)methyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

10/ 539,481

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-08-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-[(phosphonooxy)methyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-17-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[[1-[2-(phosphonooxy)ethyl]-4-piperidinyl]methoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




PAGE 1-A

● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-19-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[[1-[2-(phosphonoxy)ethyl]-4-piperidinyl]methoxy]-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 723282-71-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinazolines as inhibitors of Aurora kinase)

RN 723282-71-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385781-90-8P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[(1-hydroxy-2-methylpropan-2-yl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385781-98-6P 385781-99-7P
 385782-10-5P, N-(3,4-Difluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-18-3P 385782-26-3P,
 N-(3-Chlorophenyl)-2-[2-[[7-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
 385782-38-7P 385782-44-5P, N-(3,5-Difluorophenyl)-2-[2-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-51-4P,
 N-(3,5-Difluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
 385782-54-7P, N-(3,5-Difluorophenyl)-2-[2-[[7-[3-[(2R)-2-hydroxypropyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-81-0P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(hydroxypiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-82-1P, N-(3-Fluorophenyl)-2-[2-[[7-[3-(3-hydroxypyrrolidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-85-4P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-87-6P,
 N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
 385782-88-7P, N-(3-Fluorophenyl)-2-[2-[[7-[3-(3-hydroxypiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
 385782-89-8P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-92-3P 385782-93-4P
 723278-14-6P 723278-45-3P 723278-52-2P
 723278-60-2P 723278-68-0P 723278-76-0P
 723278-79-3P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)(ethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723278-88-4P 723278-96-4P
 723279-07-0P 723279-13-8P 723279-21-8P
 723279-29-6P 723279-32-1P 723279-38-7P
 723279-41-2P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723279-44-5P 723279-50-3P
 723279-53-6P, 2-[2-[[7-[3-[Ethyl(3-hydroxypropyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide 723279-59-2P 723279-62-7P,
 2-[2-[[7-[3-[(2-Fluoroethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide 723279-68-3P 723279-76-3P
 723279-79-6P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723279-85-4P 723279-88-7P
 723279-94-5P 723280-02-2P 723280-21-5P
 723280-29-3P 723280-41-9P 723280-49-7P
 723280-58-8P 723280-69-1P 723280-87-3P
 723280-97-5P 723281-07-0P 723281-13-8P,
 N-(2-Fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
 723281-18-3P 723281-19-4P 723281-25-2P
 723281-27-4P 723281-31-0P 723281-33-2P,
 2-[2-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(2-fluorophenyl)acetamide
 723281-36-5P 723281-37-6P, N-(2-Fluorophenyl)-2-[2-[[7-[3-[2-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723281-41-2P
 723281-47-8P 723281-52-5P 723281-54-7P


723281-59-2P 723281-61-6P, N-(2,3-Difluorophenyl)-2-[2-
 [[7-[3-[(2-hydroxyethyl)(methyl)amino]propoxy]-6-methoxyquinazolin-4-
 yl]amino]-1,3-thiazol-5-yl]acetamide 723281-65-0P
 723281-67-2P, N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[2-(2-
 hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-
 thiazol-5-yl]acetamide 723281-73-0P 723281-75-2P,
 N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-
 methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
 723281-78-5P 723281-80-9P, N-(2,3-Difluorophenyl)-2-[2-
 [[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-
 yl]amino]-1,3-thiazol-5-yl]acetamide 723281-84-3P
 723281-86-5P, N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[4-(2-
 hydroxyethyl)piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-
 thiazol-5-yl]acetamide 723281-90-1P 723281-92-3P,
 N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[(1-hydroxy-3-methylbutan-3-
 yl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-
 yl]acetamide 723281-96-7P 723281-98-9P,
 N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[(3-hydroxy-2-methylpropan-2-
 yl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-
 yl]acetamide 723282-02-8P 723282-04-0P,
 N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-
 methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
 723282-10-8P 723282-18-6P 723282-22-2P
 723282-24-4P 723282-30-2P 723282-32-4P,
 N-(2,5-Difluorophenyl)-2-[2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-
 methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
 723282-36-8P 723282-43-7P 723282-47-1P
 723282-49-3P, N-(2,4-Difluorophenyl)-2-[2-[[7-[3-[2-(2-
 hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-
 thiazol-5-yl]acetamide 723282-53-9P 723282-55-1P,
 2-[2-[[7-[3-[Cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-
 4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide
 723282-59-5P 723282-61-9P, 2-[2-[[7-[3-[Cyclopropyl(2-
 hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-
 yl]-N-(2,3-difluorophenyl)acetamide 723282-65-3P
 723282-69-7P 723282-77-7P 723282-81-3P
 723282-83-5P, N-(2,3-Difluorophenyl)-2-[2-[[7-[2-[4-(2-
 hydroxyethyl)piperazin-1-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-
 thiazol-5-yl]acetamide 723282-89-1P, N-(3-Fluorophenyl)-2-[2-[[7-
 [2-[2-(2-hydroxyethyl)piperidin-1-yl]ethoxy]-6-methoxyquinazolin-4-
 yl]amino]-1,3-thiazol-5-yl]acetamide 723282-96-0P,
 N-(3-Fluorophenyl)-2-[2-[[7-[2-[4-(2-hydroxyethyl)piperidin-1-yl]ethoxy]-6-
 methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
 723283-00-9P, 2-[2-[[7-[2-[Ethyl(4-hydroxybutyl)amino]ethoxy]-6-
 methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-
 fluorophenyl)acetamide 723283-05-4P, 2-[2-[[7-[2-[Ethyl(2-
 hydroxyethyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-
 yl]-N-(3-fluorophenyl)acetamide 723283-10-1P
 723283-15-6P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-
 (hydroxymethyl)piperidin-1-yl]propoxy]quinazolin-4-yl]amino]-1,3-thiazol-5-
 yl]acetamide 723283-21-4P 723283-27-0P,
 N-(3-Fluorophenyl)-2-[2-[[6-methoxy-7-((piperidin-4-yl)methoxy)quinazolin-
 4-yl]amino]-1,3-thiazol-5-yl]acetamide 723283-29-2P,
 2-[2-[[7-[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]piperidin-4-
 yl]methoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-
 fluorophenyl)acetamide 723283-31-6P, N-(3-Fluorophenyl)-2-[2-[[7-
 [[1-(2-hydroxyethyl)piperidin-4-yl]methoxy]-6-methoxyquinazolin-4-
 yl]amino]-1,3-thiazol-5-yl]acetamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of quinazolines as inhibitors of Aurora kinase)

RN 385781-90-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-

10/ 539,481

dimethylethyl)aminolpropoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-98-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-99-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-10-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-18-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-26-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-38-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-44-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-51-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

10/ 539,481




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-54-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[[[(2R)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-81-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-82-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-85-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-87-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-88-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-89-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-92-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,481




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-93-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-14-6 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-45-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2R)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-52-2 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[4-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-60-2 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-68-0 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-3-piperidinyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-76-0 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[ethyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-79-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-88-4 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-96-4 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[ethyl{[(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-07-0 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[(2S)-2-[[ethyl(2-hydroxyethyl)amino]methyl]-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




F

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-13-8 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-21-8 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[[(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-29-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-[[[(2-hydroxyethyl)amino]methyl]-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




F

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-32-1 ZCAPLUS

CN Carbamic acid, [[[2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl](2-hydroxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





F

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-38-7 ZCAPLUS


CN 5,7-Dioxa-2-aza-6-phosphanonanoic acid, 6-(1,1-dimethylethoxy)-2-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-8,8-dimethyl-, 1,1-dimethylethyl ester, 6-oxide (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-41-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-44-5 ZCAPLUS

CN Carbamic acid, [3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-hydroxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-50-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 3-[ethyl 3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]propyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-53-6 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-59-2 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[(2-fluoroethyl) [3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-62-7 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-fluoroethyl) (2-hydroxyethyl) amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-68-3 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-76-3 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-methoxyethyl)amino]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-79-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-85-4 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-

10/ 539,481


quinazolinyl]oxy]propyl]-2-pyrrolidinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-88-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-(2-hydroxyethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-94-5 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-

quinazolinyl]oxy]propyl]amino]-2-methylpropyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-02-2 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(3-chlorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl)methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-21-5 ZCAPLUS


CN Phosphoric acid, 2-[1-[3-[[4-[[5-[2-[(3-chlorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-29-3 ZCAPLUS


CN Phosphoric acid, 2-[4-[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-41-9 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-49-7 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-58-8 ZCAPLUS

CN Phosphoric acid, (1R)-2-[[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-1-methylethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




F

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-69-1 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(3,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,481

RN 723280-87-3 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(3,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-97-5 ZCAPLUS


CN Phosphoric acid, 1-[3-[[4-[[5-[2-[(3,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-07-0 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) [1-[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-13-8. ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-18-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2R)-1-[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-19-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-25-2 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2S)-1-[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,481

RN 723281-27-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-31-0 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[ethyl[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-33-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-36-5 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl 2-[1-[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-piperidinyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-37-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-41-2 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,481

RN 723281-47-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-52-5 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-54-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-59-2 ZCAPLUS


CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-61-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-65-0 ZCAPLUS

CN Phosphoric acid, 2-[1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-piperidinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-67-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-73-0 ZCAPLUS


CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]ethylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-75-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-78-5 ZCAPLUS


CN Phosphoric acid, 1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-80-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-84-3 ZCAPLUS


CN Phosphoric acid, 2-[4-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-86-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-90-1 ZCAPLUS


CN Phosphoric acid, 3-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-3-methylbutyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-92-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-96-7 ZCAPLUS


CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-2-methylpropyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-98-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-02-8 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl

10/ 539,481


bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-04-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-10-8 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-18-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-22-2 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-24-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-30-2 ZCAPLUS


CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]ethylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-32-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-36-8 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(2,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-43-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723282-47-1 ZCAPLUS

CN Phosphoric acid, 2-[1-[3-[[4-[[5-[2-[(2,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-piperidinyloxy]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




10/ 539,481

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-49-3 ZCAPLUS



CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-53-9 ZCAPLUS


CN Phosphoric acid, 2-[cyclopropyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-55-1 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-59-5 ZCAPLUS

CN Phosphoric acid, 2-[cyclopropyl[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-61-9 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-65-3 ZCAPLUS


CN Phosphoric acid, [1-[2-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-4-piperidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-69-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[2-[4-(hydroxymethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-77-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[2-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-81-3 ZCAPLUS


CN Phosphoric acid, 2-[4-[2-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-83-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[[7-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-89-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[2-[2-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-96-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[2-[4-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-00-9 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[2-[ethyl(4-hydroxybutyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-05-4 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[2-[ethyl(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-10-1 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) [1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-7-quinazolinyl]oxy]propyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-15-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-21-4 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[4-[[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-piperidinyl]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-27-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[[6-methoxy-7-(4-piperidinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-29-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[[1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-4-piperidiny]methoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-31-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[[1-(2-hydroxyethyl)-4-piperidiny]methoxy]-6-methoxy-4-quinazolinyl]amino]]-(9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:10468 ZCAPLUS
DOCUMENT NUMBER: 136:85826
TITLE: Preparation of substituted quinazoline derivatives and
their use as inhibitors of AURORA-2 kinase
INVENTOR(S): Mortlock, Andrew; Jung, Frederic
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000649	A1	20020103	WO 2001-SE1450	20010621
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PR, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2412592	A1	20020103	CA 2001-2412592	20010621
EP 1299381	A1	20030409	EP 2001-944061	20010621
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001011754	A	20030429	BR 2001-11754	20010621
HU 200301236	A2	20031028	HU 2003-1236	20010621
JP 2004501914	T	20040122	JP 2002-505773	20010621
CN 1496364	A	20040512	CN 2001-814620	20010621
EE 200200715	A	20040816	EE 2002-715	20010621
NZ 522696	A	20040827	NZ 2001-522696	20010621
RU 2283311	C2	20060910	RU 2003-102389	20010621

10/ 539,481

IN 2002MN01598	A	20041211	IN 2002-MN1598	20021112
ZA 2002009412	A	20040219	ZA 2002-9412	20021119
BG 107376	A	20030930	BG 2002-107376	20021211
NO 2002006010	A	20021213	NO 2002-6010	20021213
US 2003187002	A1	20031002	US 2002-311916	20021216
US 6919338	B2	20050719		
US 2006046987	A1	20060302	US 2005-70057	20050302
PRIORITY APPLN. INFO.:			EP 2000-401842	A 20000628
			WO 2001-SE1450	W 20010621
			US 2002-311916	A1 20021216

OTHER SOURCE(S): MARPAT 136:85826

GI




AB The title compds. [I; X = O, S, S:O, SO₂, NR; R = H, C₁-6alkyl; R₁ = OCH₃, 3-(4-morpholinyl)propoxy, N-methylpiperidine-4-ylmethoxy, 3-(N-methylpiperazine-4-yl)propoxy, 3-(pyrrolidine-1-yl)propoxy, (CH₃)₂N(CH₂)₃O, etc.; Q = (un)substituted 5-membered heteroarom.], pharmaceutically acceptable salts, in vivo hydrolysable esters, and amides are prepared as AURORA-2 kinase inhibitors in warm blooded animals. The title compds. together with pharmaceutical compns. containing them are also described and claimed. Thus, the title compound II was prepared and tested in vitro for the ability to arrest MCF7 cells in specific phases of the cell cycle.

IT 385780-18-7P 385780-21-2P 385780-22-3P
385780-23-4P 385780-24-5P 385780-25-6P
385780-27-8P 385784-17-8P 385784-60-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. and use as inhibitors of AURORA-2 kinase)

RN 385780-18-7 ZCAPLUS


CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-21-2 ZCAPLUS


CN 4-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-22-3 ZCAPLUS


CN 4-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-23-4 ZCAPLUS


CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-24-5 ZCAPLUS


5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-25-6 ZCAPLUS

CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-27-8 ZCAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-


10/ 539,481

quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 385784-17-8 ZCAPLUS


CN Ethanone, 1-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-60-1 ZCAPLUS

CN 5-Thiazolecarboxaldehyde, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385779-70-4P 385779-71-5P 385779-72-6P

385779-73-7P 385779-74-8P 385779-75-9P

385779-76-0P 385779-77-1P 385779-78-2P

385779-79-3P 385779-80-6P 385779-81-7P

385779-82-8P 385779-83-9P 385779-84-0P

385779-85-1P 385779-86-2P 385779-87-3P

385779-88-4P 385779-89-5P 385779-90-8P
385779-91-9P 385779-93-1P 385779-94-2P
385779-95-3P 385779-96-4P 385779-97-5P
385779-98-6P 385779-99-7P 385780-00-7P
385780-01-8P 385780-02-9P 385780-03-0P
385780-05-2P 385780-07-4P 385780-09-6P
385780-19-8P 385780-20-1P 385780-26-7P
385780-55-2P 385780-56-3P 385780-57-4P
385780-58-5P 385780-59-6P 385780-60-9P
385780-61-0P 385780-62-1P 385780-63-2P
385780-64-3P 385780-65-4P 385780-66-5P
385780-67-6P 385780-68-7P 385780-69-8P
385780-70-1P 385780-71-2P 385780-72-3P
385780-73-4P 385780-74-5P 385780-75-6P
385780-76-7P 385780-77-8P 385780-78-9P
385780-79-0P 385780-80-3P 385780-81-4P
385780-82-5P 385780-83-6P 385780-84-7P
385780-85-8P 385780-86-9P 385780-87-0P
385780-88-1P 385780-89-2P 385780-90-5P
385780-91-6P 385780-92-7P 385780-93-8P
385780-94-9P 385780-95-0P 385780-96-1P
385780-97-2P 385780-98-3P 385780-99-4P
385781-00-0P 385781-01-1P 385781-02-2P
385781-04-4P 385781-05-5P 385781-07-7P
385781-08-8P 385781-09-9P 385781-10-2P
385781-11-3P 385781-12-4P 385781-13-5P
385781-14-6P 385781-15-7P 385781-16-8P
385781-17-9P 385781-18-0P 385781-19-1P
385781-20-4P 385781-21-5P 385781-22-6P
385781-23-7P 385781-24-8P 385781-25-9P
385781-26-0P 385781-27-1P 385781-28-2P
385781-29-3P 385781-30-6P 385781-31-7P
385781-32-8P 385781-33-9P 385781-34-0P
385781-35-1P 385781-36-2P 385781-37-3P
385781-38-4P 385781-39-5P 385781-40-8P
385781-41-9P 385781-42-0P 385781-43-1P
385781-44-2P 385781-45-3P 385781-46-4P
385781-47-5P 385781-48-6P 385781-49-7P
385781-50-0P 385781-51-1P 385781-52-2P
385781-53-3P 385781-54-4P 385781-55-5P
385781-56-6P 385781-57-7P 385781-58-8P
385781-59-9P 385781-60-2P 385781-61-3P
385781-62-4P 385781-63-5P 385781-64-6P
385781-65-7P 385781-66-8P 385781-68-0P
385781-70-4P 385781-71-5P 385781-72-6P
385781-73-7P 385781-74-8P 385781-75-9P
385781-76-0P 385781-77-1P 385781-78-2P
385781-79-3P 385781-80-6P 385781-81-7P
385781-82-8P 385781-83-9P 385781-84-0P
385781-85-1P 385781-86-2P 385781-87-3P
385781-88-4P 385781-90-8P 385781-91-9P
385781-92-0P 385781-93-1P 385781-94-2P
385781-95-3P 385781-96-4P 385781-97-5P
385781-98-6P 385781-99-7P 385782-00-3P
385782-01-4P 385782-02-5P 385782-03-6P
385782-04-7P 385782-05-8P 385782-06-9P
385782-07-0P 385782-08-1P 385782-09-2P
385782-10-5P 385782-11-6P 385782-12-7P
385782-13-8P 385782-14-9P 385782-15-0P
385782-16-1P 385782-17-2P 385782-18-3P
385782-19-4P 385782-20-7P 385782-21-8P
385782-22-9P 385782-23-0P 385782-24-1P
385782-25-2P 385782-26-3P 385782-27-4P

10/ 539,481


385782-28-5P 385782-29-6P 385782-30-9P
385782-31-0P 385782-32-1P 385782-33-2P
385782-34-3P 385782-35-4P 385782-36-5P
385782-37-6P 385782-38-7P 385782-39-8P
385782-40-1P 385782-41-2P 385782-42-3P
385782-43-4P 385782-44-5P 385782-45-6P
385782-46-7P 385782-47-8P 385782-48-9P
385782-49-0P 385782-50-3P 385782-51-4P
385782-52-5P 385782-53-6P 385782-54-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of quinazoline derivs. and use as inhibitors of AURORA-2
kinase)

RN 385779-70-4 ZCAPLUS


CN 4-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-
quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-71-5 ZCAPLUS


CN 4-Thiazoleacetamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-
morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-72-6 ZCAPLUS

CN 4-Thiazoleacetamide, N-[4-(dimethylamino)phenyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-73-7 ZCAPLUS

CN 4-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-74-8 ZCAPLUS

CN 4-Thiazoleacetamide, N-(6-chloro-3-pyridinyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-75-9 ZCAPLUS

CN Morpholine, 4-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]acetyl]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-76-0 ZCAPLUS


CN Pyrrolidine, 1-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]acetyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-77-1 ZCAPLUS


CN 4-Thiazoleacetamide, N-cyclohexyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-78-2 ZCAPLUS

CN 4-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-79-3 ZCAPLUS

CN 4-Thiazolecarboxamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-80-6 ZCAPLUS


CN 4-Thiazolecarboxamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-81-7 ZCAPLUS


CN 4-Thiazolecarboxamide, N-cyclohexyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-82-8 ZCAPLUS

CN 4-Thiazolecarboxamide, N-(2-cyanoethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-83-9 ZCAPLUS

CN 4-Piperidinol, 1-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-84-0 ZCAPLUS

CN 4-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-4-pyridinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-85-1 ZCAPLUS

CN 4-Thiazolecarboxamide, N-(2-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-86-2 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-87-3 ZCAPLUS


CN 5-Thiazolecarboxamide, N-(4-fluorophenyl)-2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-88-4 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-89-5 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-90-8 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(2-cyanoethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-91-9 ZCAPLUS

CN 4-Piperidinol, 1-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-93-1 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-4-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-94-2 ZCAPLUS


CN 4-Thiazoleacetamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-N-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-95-3 ZCAPLUS

CN 4-Thiazoleacetamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-96-4 ZCAPLUS

CN 4-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-97-5 ZCAPLUS


CN 4-Piperidinol, 1-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-4-thiazolyl]acetyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-98-6 ZCAPLUS


CN 4-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385779-99-7 ZCAPLUS

CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 385780-00-7 ZCAPLUS

CN 2-Thiophenecarboxamide, N-(4-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 385780-01-8 ZCAPLUS


CN 2-Thiophenecarboxamide, N-(3-hydroxyphenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



RN 385780-02-9 ZCAPLUS


CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-4-pyridinyl-(9CI) (CA INDEX NAME)

10/ 539,481




RN 385780-03-0 ZCAPLUS

CN 2-Thiophenecarboxamide, N-(4-hydroxybutyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 385780-05-2 ZCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(aminocarbonyl)phenyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 385780-07-4 ZCAPLUS

CN 2-Thiophenecarboxamide, 5-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 385780-09-6 ZCAPLUS

CN Pentanoic acid, 5-[[[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 385780-19-8 ZCAPLUS


CN 5-Thiazolecarboxylic acid, 2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-20-1 ZCAPLUS


CN 4-Thiazoleacetic acid, 2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-26-7 ZCAPLUS

CN 4-Thiazoleacetic acid, 2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-55-2 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-56-3 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-57-4 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-58-5 ZCAPLUS


CN 5-Thiazolecarboxamide, N-[2-(hydroxymethyl)phenyl]-2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-59-6 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-60-9 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-61-0 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(cyanomethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-62-1 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methyl-5-nitrophenyl)- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-63-2 ZCAPLUS


CN 5-Thiazolecarboxamide, N-cyclopropyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-64-3 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(4-nitrophenyl)methyl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-65-4 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-66-5 ZCAPLUS


CN 5-Thiazolecarboxamide, N-(2-furanylmethyl)-2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-67-6 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-68-7 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-69-8 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-thienylmethyl)]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-70-1 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(2,2-dimethylpropyl)-2-[[[6-methoxy-7-[[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-71-2 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(2,6-difluorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-72-3 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-73-4 ZCAPLUS


CN 5-Thiazolecarboxamide, N-(4-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-74-5 ZCAPLUS


CN 5-Thiazolecarboxamide, N-(2-fluoro-5-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-75-6 ZCAPLUS


CN 5-Thiazolecarboxamide, N-[(4-fluorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-76-7 ZCAPLUS


CN 5-Thiazolecarboxamide, N-[(3,4-difluorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-77-8 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-78-9 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-79-0 ZCAPLUS


CN 5-Thiazolocarboxamide, N-1H-indol-5-yl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-80-3 ZCAPLUS


CN 5-Thiazolecarboxamide, N-(3-cyanophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-81-4 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(2,4-difluorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-82-5 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-83-6 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-84-7 ZCAPLUS


CN 5-Thiazolecarboxamide, N-[(2-aminophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-85-8 ZCAPLUS


CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-86-9 ZCAPLUS


CN 5-Thiazolecarboxamide, N-[(1-hydroxycyclohexyl)methyl]-2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-87-0 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(pyrazinylmethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-88-1 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-89-2 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(4-chlorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-90-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl-(9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-91-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-92-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-93-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-94-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-95-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-96-1 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-97-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-98-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-99-4 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-00-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-[2-(hydroxymethyl)phenyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-01-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-[1-(hydroxymethyl)-2-methylpropyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-02-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-hydroxyethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl-(9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-04-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-05-5 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-07-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(cyanomethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-08-8 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methyl-5-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-09-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-chloro-2-pyridinyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-10-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-11-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-12-4 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-13-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-14-6 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-15-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-hydroxy-2-phenylethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-16-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-[3-(1-hydroxyethyl)phenyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-17-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,2-dimethylpropyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-18-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluoro-4-methoxyphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-19-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-20-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-21-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(4-chloro-2-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-22-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-fluoro-4-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-23-7 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-24-8 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-25-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-1H-indol-5-yl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-26-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-27-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-cyanophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-28-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(5-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-29-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-chloro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-30-6 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-31-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-32-8 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-33-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-34-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-chlorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-35-1 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-36-2 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-37-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-38-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-39-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-40-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-41-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-chloro-2-pyridinyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-42-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-43-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-44-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluoro-4-methoxyphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-45-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(4-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-46-4 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-47-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyloxy)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-48-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(4-chloro-2-fluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyloxy)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-49-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluoro-5-methylphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-50-0 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-51-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-52-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-fluoro-4-methylphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-53-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-cyanophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-54-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(5-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-55-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-56-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-57-7 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-58-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-59-9 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME).



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-60-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-61-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-chlorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-62-4 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)]-(9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-63-5 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-64-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-65-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-66-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(6-methyl-2-pyridinyl)-(9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-68-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(5-chloro-2-pyridinyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-70-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-71-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-72-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-cyanophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-73-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-fluoro-4-methylphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-74-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluoro-4-methoxyphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-75-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-76-0 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methyl-2-pyridinyl)-(9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-77-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-78-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(4-chloro-2-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-79-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-fluoro-5-methylphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-80-6 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-81-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-82-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(5-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-83-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-84-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-85-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-86-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-87-3 ZCAPLUS



CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-(dimethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-88-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-90-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-91-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidiny)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-92-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-93-1 ZCAPLUS



CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-94-2 ZCAPLUS



CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-95-3 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-amino-2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-96-4 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-(cyclohexylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)





|
F

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-97-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-98-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-99-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-00-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-01-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-02-5 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-(4-acetyl-1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-03-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-04-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-05-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-06-9 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-07-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-08-1 ZCAPLUS

CN L-Alanine, N-[3-[[4-[[5-[2-[(3,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-09-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-10-5 ZCAPLUS



CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-11-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-12-7 ZCAPLUS

CN L-Alanine, N-[3-[[4-[[5-[2-[(3-chlorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-13-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Cl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-14-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-amino-2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




Cl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-15-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(cyclohexylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-16-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-17-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]methyamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-18-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385782-19-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,481

NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-20-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-21-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-22-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-23-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-24-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-25-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-26-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-27-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,481




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-28-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[[[(2S)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-29-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[[[(2R)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-30-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(1-hydroxypropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-31-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-32-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A




Cl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-33-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-34-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(dimethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,481

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-35-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-
[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-36-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(1-
piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-37-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[4-[2-

10/ 539,481

(dimethylamino)ethyl]-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-38-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-39-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-40-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-41-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-42-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-43-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-44-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-45-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-46-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidiny)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-47-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]methoxy]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-48-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-49-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-50-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-51-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-52-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-53-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[[[(2S)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-54-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[[[(2R)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385782-55-8P 385782-56-9P 385782-57-0P
 385782-58-1P 385782-59-2P 385782-60-5P
 385782-61-6P 385782-62-7P 385782-63-8P
 385782-64-9P 385782-65-0P 385782-66-1P
 385782-67-2P 385782-68-3P 385782-69-4P
 385782-70-7P 385782-71-8P 385782-72-9P
 385782-73-0P 385782-74-1P 385782-75-2P
 385782-76-3P 385782-77-4P 385782-78-5P
 385782-79-6P 385782-80-9P 385782-81-0P
 385782-82-1P 385782-83-2P 385782-84-3P
 385782-85-4P 385782-86-5P 385782-87-6P
 385782-88-7P 385782-89-8P 385782-90-1P
 385782-92-3P 385782-93-4P 385782-94-5P
 385782-95-6P 385782-96-7P 385782-97-8P
 385782-98-9P 385782-99-0P 385783-00-6P
 385783-01-7P 385783-02-8P 385783-03-9P
 385783-04-0P 385783-05-1P 385783-06-2P
 385783-07-3P 385783-08-4P 385783-09-5P
 385783-10-8P 385783-11-9P 385783-12-0P
 385783-13-1P 385783-14-2P 385783-15-3P
 385783-16-4P 385783-17-5P 385783-18-6P
 385783-19-7P 385783-20-0P 385783-21-1P
 385783-22-2P 385783-23-3P 385783-24-4P
 385783-25-5P 385783-27-7P 385783-28-8P


385783-29-9P 385783-30-2P 385783-31-3P
 385783-32-4P 385783-33-5P 385783-34-6P
 385783-35-7P 385783-36-8P 385783-37-9P
 385783-42-6P 385783-44-8P 385783-46-0P
 385783-48-2P 385783-50-6P 385783-52-8P
 385783-54-0P 385783-56-2P 385783-58-4P
 385783-60-8P 385783-62-0P 385783-64-2P
 385783-66-4P 385783-68-6P 385783-69-7P
 385783-71-1P 385783-73-3P 385783-75-5P
 385783-77-7P 385783-79-9P 385783-81-3P
 385783-83-5P 385783-85-7P 385783-87-9P
 385783-89-1P 385783-91-5P 385783-93-7P
 385783-95-9P 385783-97-1P 385784-05-4P
 385784-07-6P 385784-08-7P 385784-09-8P
 385784-10-1P 385784-12-3P 385784-13-4P
 385784-15-6P 385784-20-3P 385784-22-5P
 385784-26-9P 385784-28-1P 385784-31-6P
 385784-33-8P 385784-35-0P 385784-37-2P
 385784-40-7P 385784-41-8P 385784-43-0P
 385784-45-2P 385784-47-4P 385784-49-6P
 385784-51-0P 385784-53-2P 385784-55-4P
 385784-57-6P 385784-59-8P 385784-62-3P
 385785-60-4P 385843-31-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of quinazoline derivs. and use as inhibitors of AURORA-2
 kinase)

RN 385782-55-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-(1-
 piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-56-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[4-(2-
 propenyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX
 NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-57-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-58-1 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,5-difluorophenyl)-(9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-59-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino] - (9CI)
(CA INDEX NAME)

PAGE 1-A







ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-60-5 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-61-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-62-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-63-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,481


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-64-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-65-0 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-(4-acetyl-1-piperazinyl)propoxy]-6-methoxy-4-

10/ 539,481


quinazolinyl]amino]-N-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-66-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-67-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[4-(2-

10/ 539,481


hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-68-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-69-4 ZCAPLUS

10/ 539,481


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-70-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,481

RN 385782-71-8 ZCAPLUS



CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-72-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[(2-hydroxypropyl) amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-73-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-74-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-[4-(2-(4-morpholinyl)ethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-75-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-76-3 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-77-4 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-amino-2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-78-5 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[[2-(dimethylamino)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-79-6 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-80-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-81-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-82-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-83-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-84-3 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-(4-acetyl-1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-85-4 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-86-5 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-87-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-88-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidiny)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-89-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


10/ 539,481 .



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-90-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-92-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-93-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-94-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-95-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-96-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-hydroxy-1,1-dimethylethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-97-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-ethyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-98-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-99-0 ZCAPLUS


CN Glycine, N-(3-chloro-4-fluorophenyl)-N-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-00-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(cyanomethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-01-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-cyanoethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-02-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-N-[2-(1,1-dimethylethoxy)ethyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-03-9 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl-N-2-propenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-04-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-1,3-benzodioxol-5-yl-N-ethyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-05-1 ZCAPLUS

CN Benzoic acid, 4-[butyl[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-06-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-ethyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-07-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-08-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl- (9CI) (CA INDEX NAME)

10/ 539,481


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-09-5 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-10-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-11-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-12-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-13-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-14-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-15-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-16-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-17-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-18-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-19-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidiny)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,481

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-20-0 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-21-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-22-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidiny)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-23-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-24-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,481

RN 385783-25-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-27-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidiny)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-28-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidiny)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-29-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-30-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,481

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-31-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[(2S)-3-(4-acetyl-1-piperazinyl)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,5-difluorophenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-32-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-33-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-34-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-35-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-36-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[(2S)-3-(4-acetyl-1-piperazinyl)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-37-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-42-6 ZCAPLUS


CN 5-Thiazoleacetamide, α -hydroxy-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-44-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-α-hydroxy-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-46-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-α-hydroxy-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-48-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-α-hydroxy-2-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-50-6 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-α-hydroxy-2-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-52-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-α-(hydroxyimino)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-54-0 ZCAPLUS


CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)

10/ 539,481




RN 385783-56-2 ZCAPLUS

CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 385783-58-4 ZCAPLUS

CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 385783-60-8 ZCAPLUS


CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 385783-62-0 ZCAPLUS


CN 2-Thiophenecarboxamide, N-[2-(hydroxymethyl)phenyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,481



RN 385783-64-2 ZCAPLUS


CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 385783-66-4 ZCAPLUS


CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10/ 539,481



RN 385783-68-6 ZCAPLUS


CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 385783-69-7 ZCAPLUS


CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

10/ 539,481



RN 385783-71-1 ZCAPLUS


CN 2-Thiophenecarboxamide, N-[3-(2-hydroxyethyl)phenyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 385783-73-3 ZCAPLUS


CN 2-Thiophenecarboxamide, N-(3-fluoro-4-methoxyphenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,481




RN 385783-75-5 ZCAPLUS

CN 2-Thiophenecarboxamide, N-(4-fluoro-2-methylphenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 385783-77-7 ZCAPLUS

CN 2-Thiophenecarboxamide, N-(2-fluoro-5-methylphenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 385783-79-9 ZCAPLUS

CN 2-Thiophenecarboxamide, N-(3-cyanophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 385783-81-3 ZCAPLUS

CN 2-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 385783-83-5 ZCAPLUS

CN 2-Thiophenecarboxamide, N-(2-chlorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 385783-85-7 ZCAPLUS


CN 3-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



10/ 539,481


RN 385783-87-9 ZCAPLUS

CN 3-Thiophenecarboxamide, N-(4-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 385783-89-1 ZCAPLUS

CN 3-Thiophenecarboxamide, N-(3-hydroxyphenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 385783-91-5 ZCAPLUS

CN 3-Thiophenecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 385783-93-7 ZCAPLUS

CN 3-Thiophenecarboxamide, N-(3-chloro-4-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 385783-95-9 ZCAPLUS

CN 3-Thiophenecarboxamide, N-[(2,4-difluorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 385783-97-1 ZCAPLUS

CN 3-Thiophenecarboxamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 385784-05-4 ZCAPLUS

CN 3-Thiophenecarboxamide, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl-(9CI) (CA INDEX NAME)




RN 385784-07-6 ZCAPLUS

CN 3-Thiophenecarboxamide, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 385784-08-7 ZCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 385784-09-8 ZCAPLUS

CN 3-Thiophenecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 385784-10-1 ZCAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 385784-12-3 ZCAPLUS

CN 3-Thiophenecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 385784-13-4 ZCAPLUS

CN 3-Thiophenecarboxamide, 5-ethyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 385784-15-6 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-(4-phenyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-20-3 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-22-5 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-26-9 ZCAPLUS


CN Acetamide, N-[4-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-28-1 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-[5-phenyl-4-(trifluoromethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-31-6 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-[4-

10/ 539,481


(trifluoromethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-33-8 ZCAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)-2-thiazolyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-35-0 ZCAPLUS


CN 4-Quinazolinamine, N-(4,5-dimethyl-2-thiazolyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-37-2 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-(4-methyl-2-thiazolyl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-40-7 ZCAPLUS


CN Ethanone, 1-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-5-thiazolyl]-, oxime (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-41-8 ZCAPLUS

CN Carbamic acid, [2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-43-0 ZCAPLUS

CN Ethanone, 1-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-5-thiazolyl]-, O-methyloxime (9CI) (CA INDEX NAME)

10/ 539,481


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-45-2 ZCAPLUS


CN Ethanone, 1-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-5-thiazolyl]-, O-phenyloxime (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-47-4 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-[5-(4-methoxyphenyl)-2-thiazolyl]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-49-6 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-(5-phenyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-51-0 ZCAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-2-thiazolyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-53-2 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-[5-(1-methylethyl)-2-thiazolyl]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-55-4 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-[5-(phenylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-57-6 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-(5-methyl-2-thiazolyl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-59-8 ZCAPLUS

CN 4-Quinazolinamine, N-(5-butyl-2-thiazolyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)


10/ 539,481



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-62-3 ZCAPLUS


CN 5-Thiazolecarboxaldehyde, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, oxime (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385785-60-4 ZCAPLUS

CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385843-31-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-[2(or 3)-methoxyphenyl]-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-Me

PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385784-81-6P 385784-82-7P 385784-83-8P

385784-91-8P 385784-92-9P 385784-98-5P

385785-12-6P 385785-13-7P 385785-35-3P


385785-36-4P 385785-50-2P 385785-51-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinazoline derivs. and use as inhibitors of AURORA-2 kinase)

RN 385784-81-6 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-82-7 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-83-8 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-91-8 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-92-9 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-98-5 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385785-12-6 ZCAPLUS

CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385785-13-7 ZCAPLUS

CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-2-thiazolyl-
(9CI) (CA INDEX NAME)



CN 5-Thiazoleacetic acid, α -hydroxy-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



CN 3-Thiophenecarboxylic acid, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)